This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


VBL Therapeutics

Drug Names(s): Ad-PPE-Fas-c, GT-111, VB-111

Description: VB-111 is a tissue and condition specific vascular disrupting and anti-angiogenic agent based on a novel Vascular Targeting System (VTS) which contains the modified angiogenic specific pre-proendothelin promoter (PPE), and a FAS/TNF receptor chimeric transgene (Fas-C). The Fas-c protein is an engineered protein made of two parts: a part of a receptor called ‘TNF receptor’ to which a ligand, TNF-alpha, attaches, as well as a part of the Fas protein which activates cell death. When TNF-alpha attaches to the Fas-c protein, the Fas component of the protein is expected to cause the death of the developing blood vessels. As a result, the medicine is expected to stop the formation of new blood vessels which will prevent the growth of a tumor.

VB-111 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug